10027020Preclinical development of an innovative electric field therapy device for the treatment of GlioblastomaClosedCollaborative R&DInnovate UKGlioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and the 5-year survival rate is ~3.4%. Electrotherapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the only available electrotherapy device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness. QV Bioelectronics (QVB) is developing a novel approach to deliver electrotherapy in a focal and continuous manner that will potentially double glioblastoma patient life expectancy, leading to up to 10-times higher 5-year survival rates whilst overcoming quality-of-life issues associated with the existing electrotherapy treatment. QVB has developed a working prototype and will perform pre-clinical safety testing as part of this Innovate UK funded project as well as working on other development aspects of their technology. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, with our research and innovation hub creating a significant number of jobs in the UK, creating a combined global market opportunity worth over £3Bn/year. This will cement the UK's position as global leaders in the growing field of bioelectronics.